Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR442970 in adults with hidradenitis suppurativa
NL-OMON60569Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SAR442970 with Placebo (2 arms). Primary endpoint: Percentage of biologic and small molecule immunosuppressive naive participants achieving HiSCR50. Started Dec 2023; status: completed.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60569.